Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

LC-MS experiments of SARS-CoV2 Receptor Binding Domain WT

ABSTRACT: Antigen specific humoral immunity can be characterized by the analysis of serum antibodies. While serological assays for the measurement of antibody levels and of neutralization potential against SARS-CoV-2 are available, these are not quantitative in the biochemical sense. Yet, understanding the biology of COVID-19 would need an unambiguous, complete, quantitative, comparable measurement of specific serum antibodies. Here we describe a fluorescent, dual-titration immunoassay, which provides the physico-chemical parameters that are both necessary and sufficient to quantitatively characterize the humoral immune response. We used recombinant Receptor Binding Domain of SARS-CoV-2 as antigen on microspot arrays and varied the concentration of both the antigen and serum antibodies from vaccinated persons to obtain a measurement matrix of binding data. Binding curves were fitted using a novel algorithm to obtain thermodynamic variables of binding. We defined the standard state for a system of serum antibodies and antigen and showed how a normalized generalized logistic function is related to thermodynamic activity, standard concentration and activity coefficient. The utility of the method is demonstrated by defining the composition of tested sera with respect to immunoglobulin classes, affinity, concentration, and thermodynamic activity. The proposed fluorescent dual-titration microspot immunoassay can generate truly quantitative serological data that is suitable for immunological, medical and systems biological analysis.

INSTRUMENT(S): Orbitrap Exploris 480

ORGANISM(S): Recombinant Sars Coronavirus

SUBMITTER: Daniel Nyberg Larsen

LAB HEAD: Peter Højrup

PROVIDER: PXD040415 | Pride | 2025-02-21

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	20200715_RBD_Report.docx	Other
	EXP3_00213_DNL.mgf	Mgf
	EXP3_00213_DNL.raw	Raw
	EXP3_00213_DNL.xml	Xml
	EXP3_00214_DNL.mgf	Mgf

Items per page:

1 - 5 of 15

Similar Datasets

Profiling antibody function on antigen arrays

Project description:Humoral immune responses are traditionally characterized by determining the presence and quality of antibodies specific for certain antigens. Arraying of large numbers of antigens allows the parallel measurement of antibodies, generating patterns called antibody profiles. Functional characterization of these antibodies could help draw an even more informative map of an immune response. To generate functional antibody profiles we simultaneously tested not only IgM, IgG and IgA binding to but also complement activation by a panel of endogenous and exogenous antigens printed as microarrays, using normal and autoimmune human sera. We show that complement activation by a particular antigen in a given individual cannot be predicted by the measurement of antigen specific antibodies, in spite of a general correlation between the amount of antigen-bound antibody and the deposited C3 fragments. This is due to both differences in the isotypes that dominate in the recognition of an antigen and individual variations for a given isotype, resulting in altered complement activation potential. Thus, antigen specific C3 deposition can be used as an additional parameter in immune response monitoring. This is exemplified by comparing the coordinates of antigens, used for the diagnosis of systemic lupus erythematosus, of normal and autoimmune serum samples in a two-dimensional space derived from C3 deposition and antibody binding. Since cleavage fragments of C3 mediate important immunological processes we propose that measurement of their deposition on antigen microarrays, in addition to antibody profiling, can provide useful functional signature about the tested serum. Keywords: IgM immuneprofile, antigen array IgM, IgG, IgA and C3 binding in 30 human serum samples were examined using custom-made protein arrays

2010-05-15 | E-GEOD-12943 | biostudies-arrayexpress

Profiling antibody function on antigen arrays

2008-12-01 | GSE12943 | GEO

Proteomic analysis of antigen-specific serum and gut antibodies in celiac disease patients

Project description:Comparison of serum and gut antibodies against two major antigens in celiac disease patients, the autoantigen transglutaminase 2 (TG2) and a deamidated gluten peptide (DGP) from food. The antigen-specific antibodies were affinity-purified from isolated total IgA of serum or gut biopsy secretions or from whole serum samples. Individual clonotypes could be identified among the purified antibodies based on matching to a database of IgH sequences obtained from antigen-specific gut plasma cells of the same patients.

2017-07-14 | MSV000081328 | MassIVE

Immunoglobulin V-gene usage among human serum IgA with or without specificity to the autoantigen transglutaminase 2

Project description:To study V-gene usage among antigen-specific and non-antigen-specific serum IgA antibodies in celiac disease patients, purified antibody fractions were subjected to proteomic analysis. Patients either had eastablished, untreated disease with severe intestinal inflammation or "potential" celiac disease characterized by presence of antibodies but no or mild inflammation. Quantification of the fraction of antibodies using different IGHV segments revealed that antibodies specific to the autoantigen transglutaminase 2 (TG2) displayed a bias toward usage of IGHV5-51 in agreement with previous observations. The fraction of antibodies using IGHV5-51 correlated with the degree of intestinal inflammation, indicating that production of hallmark IGHV5-51 anti-TG2 antibodies coincides with onset of clinical celiac disease.

2019-07-09 | PXD013777 | Pride

Titration of 124 antibodies using CITE-Seq on human PBMCs

Project description:Titration of 124 antibodies using CITE-Seq on human PBMCs

| PRJNA880327 | ENA

E-GEOD-14668

Project description:B-Cell Gene Signature with Massive Intrahepatic Production of Antibodies to Hepatitis B Core Antigen in HBV-Associated Acute Liver Failure

2025-01-24 | E-GEOD-14668 | ExpressionAtlas

The Trypanosoma cruzi Antigen and Epitope Atlas: discovery of antibody specificities in human Chagas Disease patients across human populations

Project description:These assays represent an antigen discovery screening, and epitope mapping characterization. In this screening two complete proteomes from Trypanosoma cruzi, from two different strains (CL-Brener, Sylvio X10), were displayed in the form of short peptides (tiling array, overlapped) and assayed with pooled serum samples (antibodies) from Chagas Disease patients and matched negative (healthy) subjects selected from 6 geographic regions across the Americas. Peptide arrays (slides) were incubated with pooled serum samples (primary antibodies), washed, and then incubated with a fluorescently-labeled anti-human IgG commercial antibody (secondary antibodies). Raw readouts of fluoresence (signal), as well as normalized signal values are provided in this submission for all samples analyzed. All samples were analyzed in duplicate.

2022-08-20 | E-MTAB-11651 | biostudies-arrayexpress

Epitope profiling by deep sequencing

Project description:Rapid profiling of the Neisserial NadA antigen regions recognized by serum antibodies using massively parallel sequencing of antigen-specific libraries

| PRJEB7370 | ENA

Wild-type and single-O-antigen repeat outer-membrane vesicles induce equivalent protection against homologous and heterologous Salmonella challenge

Project description:Lipopolysaccharide O-antigen is an immunodominant target of protective antibodies. Variation in O-antigen structures limits antibody-mediated cross-protection between closely-related pathogens including Salmonella Typhimurium (STm) and S. Enteritidis (SEn). Bacterial outer membrane vesicles (OMV) are vaccine platforms presenting surface antigens in their natural conformations. To assess how O-antigen lengths impact antibody responses and control of homologous or heterologous infection, mice were immunized with STm-OMV containing wild-type O-antigen unit repeats (wt-OMV), ≤1 O-antigen unit (wzy-OMV), or no O-antigen units (wbaP-OMV) respectively and challenged with either STm or SEn. Unexpectedly, anti-STm LPS IgG and protection to STm were comparable after immunization with either wt-OMV or wzy-OMV. Anti-porin responses were elevated after immunization with wzy-OMV and wbaP-OMV. A single immunization with any OMV induced minimal cross-protection against SEn, except in blood. In contrast, boosting with O-antigen-expressing OMV enhanced control of SEn infections by >10-fold. These results suggest that i) Antibody to single or variable-length O-antigen units are comparably protective against Salmonella; ii) Antigens other than immunodominant O-antigens may be targets of cross-reactive antibodies that moderate bacterial burdens; iii) Boosting can enhance the level of cross-protection against related Salmonella serovars and iv) High tissue burdens of Salmonella can be present in the absence of detectable bacteraemia.

2025-02-21 | PXD056628 | Pride

Proteomic identification of anti-tetanus toxoid antibodies from human serum (HD1)

Project description:Proteomic identification and characterization of antibodies comprising the serological response to antigen can provide unique insight into the functional dynamics of adaptive immunity. We have developed a novel method to overcome the technical challenges which previously limited the direct analysis of immunoglobulin proteins in serum, as demonstrated by the identification of human anti-tetanus toxoid (TT) immunoglobulin G (IgG) proteins following booster vaccination. We analyzed the serum IgG repertoire across four time-points corresponding to pre-vaccination, 7 days, 3 months, and 9 months post vaccination. Antigen-specific antibodies were affinity purified against immobilized TT protein and sequenced by bottom-up nanoLC-MS/MS. Interpretation of mass spectra required a custom reference database of IgG heavy and light chain variable sequences determined by NextGen RNA sequencing of the donor's circulating plasmablasts and memory B cells following booster vaccination.

2014-04-24 | PXD000917 | Pride